SEC For	m 4															
FORM 4 UNITED ST				TATE	es se			ES AND		NGE C	ОММІ	SSION		OMB /	APPROV	/AL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed pu	ursuant	to Sectior	n 16(a	a) of the Secu	urities Exchar	-	Estima			MB Number: 3235-0287 timated average burden urs per response: 0.5		
1. Name and Address of Reporting Person* <u>Resnick Joshua</u>				2	 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol <u>Aerovate Therapeutics, Inc.</u> [AVTE] 										. ,	s) to Issuer 10% Owner
(Last) (First) (Middle) C/O AEROVATE THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/21/2022							Officer (give title Other (specify below) below)				
930 WINTER STREET, SUITE M-500 (Street) WALTHAM, MA 02451				4	. If Ame	ndment, I	Date	of Original Fi	led (Month/D	Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	,	(Zip)							<u> </u>						
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)					ction 2A. Deemed Execution Date,		, 3. 4. Secur , Transaction Dispose Code (Instr. 5)		ities Acquir d Of (D) (Ins	ed (A) or	5. Amou Securitie Beneficia	nt of s ally following	Form:	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	/ Amount	(A) or (D)	(A) or Price Tra		saction(s) . 3 and 4)			Instr. 4)
		-	Fable II - Der (e.g					uired, Dis s, options				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code	saction (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$12.26	06/21/2022		A		12,500		(1)	06/20/2032	Common Stock	12,500	\$0	12,500	,	D ⁽²⁾	

Explanation of Responses:

1. The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

/s/ George A. Eldridge,	
Attorney_in_Eact	

** Signature of Reporting Person Date

06/22/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.